Breakthrough: China’s First Approved Solid Tumor CAR-T Therapy Paves the Way for Industry Transformation

The National Medical Products Administration has approved the listing of KaiXing Life Technology (Shanghai) Co., Ltd.’s CAR-T therapy, named Kailimei, for the treatment of advanced gastric/esophagogastric junction adenocarcinoma. This marks the global debut of a CAR-T therapy for solid tumor treatment, a significant milestone in the field of cell and gene therapy (CGT). The breakthrough by KaiXing Life Technology signifies China’s leap from “keeping pace” to ‘leading’ in the forefront of CGT. The approval follows another groundbreaking news in the market just two months earlier. HuaDao Biology’s 1st class new drug, WanJiaolunSai injection, intended for the treatment of refractory relapsed…